JP2014507442A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507442A5
JP2014507442A5 JP2013555521A JP2013555521A JP2014507442A5 JP 2014507442 A5 JP2014507442 A5 JP 2014507442A5 JP 2013555521 A JP2013555521 A JP 2013555521A JP 2013555521 A JP2013555521 A JP 2013555521A JP 2014507442 A5 JP2014507442 A5 JP 2014507442A5
Authority
JP
Japan
Prior art keywords
expression cassette
tbx5
mef2c
subject
hand2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013555521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/026113 external-priority patent/WO2012116064A1/en
Publication of JP2014507442A publication Critical patent/JP2014507442A/ja
Publication of JP2014507442A5 publication Critical patent/JP2014507442A5/ja
Pending legal-status Critical Current

Links

JP2013555521A 2011-02-22 2012-02-22 心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復 Pending JP2014507442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445390P 2011-02-22 2011-02-22
US61/445,390 2011-02-22
PCT/US2012/026113 WO2012116064A1 (en) 2011-02-22 2012-02-22 Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes

Publications (2)

Publication Number Publication Date
JP2014507442A JP2014507442A (ja) 2014-03-27
JP2014507442A5 true JP2014507442A5 (https=) 2015-04-16

Family

ID=45922797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555521A Pending JP2014507442A (ja) 2011-02-22 2012-02-22 心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復

Country Status (6)

Country Link
US (2) US9017661B2 (https=)
EP (1) EP2678354A1 (https=)
JP (1) JP2014507442A (https=)
AU (1) AU2012220702B2 (https=)
CA (1) CA2827329A1 (https=)
WO (1) WO2012116064A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776071B1 (en) 2011-11-09 2018-08-08 Cedars-Sinai Medical Center Transcription factor-based generation of pacemaker cells and methods of using same
CA2934065C (en) * 2013-10-25 2023-05-09 Qurgen, Inc. Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming
JP2015213441A (ja) * 2014-05-08 2015-12-03 学校法人慶應義塾 心筋様細胞の作製方法及びそれに用いる培地
WO2016022992A1 (en) * 2014-08-07 2016-02-11 Duke University Compositions and methods for the reprogramming of cells into cardiomyocytes
KR101530278B1 (ko) * 2014-09-04 2015-06-24 부산대학교 산학협력단 심근전환유전자 및 심혈관재생유전자를 포함하는 아데노부속바이러스를 유효성분으로 포함하는, 허혈성 심장질환 예방 또는 치료용 조성물
US9885018B1 (en) 2015-03-16 2018-02-06 The Regents Of The University Of Colorado, A Body Corporate High efficiency reprogramming of fibroblasts into cardiomyocytes
US20200216813A1 (en) * 2017-06-21 2020-07-09 Mogrify Limited Cell reprogramming to cardiomyocytes
WO2019036086A1 (en) * 2017-08-15 2019-02-21 The Board Of Regents Of The University Of Texas System CARDIAC REPAIR BY REPROGRAMMING CARDIAC FIBROBLASTS ADULT TO CARDIOMYOCYTES
US12042525B2 (en) 2018-01-05 2024-07-23 University Of Houston System Serum response factor regenerates senescent cells
GB2571704A (en) * 2018-02-22 2019-09-11 Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen Prevention or treatment of cardiac arrhytmia and sudden cardiac death
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
EP1085910A2 (en) * 1998-05-30 2001-03-28 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
WO2002002148A2 (en) * 2000-06-30 2002-01-10 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
WO2007056759A2 (en) * 2005-11-08 2007-05-18 University Of South Florida Improved method of stem cell therapy for cardiovascular repair
WO2008088882A2 (en) * 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
JP5988961B2 (ja) * 2010-04-28 2016-09-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 心筋細胞を発生させるための方法
JP2013534525A (ja) * 2010-06-23 2013-09-05 ヴィヴォスクリプト，インコーポレイテッド 心臓疾患の治療のために遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法

Similar Documents

Publication Publication Date Title
JP2014507442A5 (https=)
Keating et al. Nesiritide: a review of its use in acute decompensated heart failure
Kataoka et al. The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction
Boerrigter et al. Des-serine-proline brain natriuretic peptide 3–32 in cardiorenal regulation
Sezai et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction
Yahud et al. Cannabis induced cardiac arrhythmias: a case series
Pilote et al. Stiff left atrial syndrome.
Granton et al. Management of severe pulmonary arterial hypertension
Strain The use of recombinant human B‐type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure
Flint et al. Effect of GL enzyme (a highly purified form of hyaluronidase) on mortality after myocardial infarction
Rossi et al. Effects of ivabradine on right ventricular systolic function in patients with chronic obstructive pulmonary disease and cor pulmonale
Nagashima et al. Marked improvement of left ventricular function after parathyroidectomy in a hemodialysis patient with secondary hyperparathyroidism and left ventricular dysfunction
Nojiri et al. Effect of low-dose human atrial natriuretic peptide on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer: a double-blind, placebo-controlled study
Bettencourt Brain natriuretic peptide (nesiritide) in the treatment of heart failure
Katsaragakis et al. Prophylactic preoperative levosimendan administration in heart failure patients undergoing elective non-cardiac surgery: a preliminary report
Savale et al. Management of acutely decompensated pulmonary hypertension
Sagawa et al. Long-term performance of right ventricular implantable cardioverter-defibrillator leads in arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy
Ji et al. Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement
He et al. Clinical Efficacy of Blood Ultrafiltration Therapy in Patients with Acute Decompensated Chronic Heart Failure
Imamura et al. Shorter heart failure duration is a predictor of left ventricular reverse remodeling during adaptive servo-ventilator treatment in patients with advanced heart failure
Ho et al. Complete atrioventricular block complicating acute anterior myocardial infarction can be reversed with acute coronary angioplasty
Li et al. Fasting blood glucose at admission and survival in patients with dilated cardiomyopathy: a single-center cohort study
Keber et al. Paricalcitol as an antiproteinuric agent can result in the deterioration of renal and heart function in a patient with Fabry disease
Skov et al. Wild-type transthyretin amyloid cardiomyopathy: expect the unexpected—a case report
Ahrar et al. Efficacy of Intraoperative Radio frequency Ablation in Patients Undergoing Mitral Valve Replacement for Rheumatic Heart Disease Complicated by Chronic Atrial Fibrillation.